Drug Profile
ARQ 621
Alternative Names: ARQ-621Latest Information Update: 20 Jan 2020
Price :
$50
*
At a glance
- Originator ArQule
- Developer Merck & Co
- Class Antineoplastics; Small molecules
- Mechanism of Action KIF11 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Haematological malignancies; Solid tumours
Most Recent Events
- 16 Jan 2020 ArQule has been acquired and merged into Merck & Co
- 31 Mar 2014 Discontinued - Phase-I for Haematological malignancies (late-stage disease) in USA before March 2014 (Intravenous)
- 31 Mar 2014 Discontinued - Phase-I for Solid tumours (metastatic disease) in USA before March 2014 (Intravenous)